Several other brokerages have also issued reports on ESPR. Bank of America upgraded shares of Esperion Therapeutics from an underperform rating to a neutral rating in a research note on Monday, May 6th. Stifel Nicolaus reiterated a buy rating on shares of Esperion Therapeutics in a research note on Thursday, June 13th. Citigroup set a $73.00 price target on shares of Esperion Therapeutics and gave the company a buy rating in a research note on Tuesday, May 28th. ValuEngine downgraded shares of WideOpenWest from a hold rating to a sell rating in a research report on Friday, June 28th. Finally, Credit Suisse Group set a €50.00 ($58.14) price objective on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Monday, May 6th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Esperion Therapeutics presently has an average rating of Buy and an average target price of $74.45.
Shares of ESPR stock opened at $45.61 on Friday. Esperion Therapeutics has a 1 year low of $36.06 and a 1 year high of $60.99. The company has a fifty day simple moving average of $48.58. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -6.05 and a beta of 1.73.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $2.43. The business had revenue of $145.42 million during the quarter, compared to analyst estimates of $69.35 million. During the same quarter in the previous year, the firm posted ($1.73) earnings per share. As a group, equities research analysts predict that Esperion Therapeutics will post -2.65 earnings per share for the current year.
In other news, CEO Timothy M. Mayleben acquired 5,000 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was bought at an average price of $46.00 per share, with a total value of $230,000.00. Following the transaction, the chief executive officer now directly owns 66,163 shares in the company, valued at approximately $3,043,498. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.70% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Advisor Group Inc. boosted its holdings in shares of Esperion Therapeutics by 44.4% during the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 291 shares during the period. Parallel Advisors LLC bought a new stake in shares of Esperion Therapeutics during the 1st quarter worth about $80,000. Marshall Wace North America L.P. bought a new stake in shares of Esperion Therapeutics during the 1st quarter worth about $164,000. Marshall Wace LLP bought a new stake in shares of Esperion Therapeutics during the 1st quarter worth about $186,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of Esperion Therapeutics by 288.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,045 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,745 shares during the period.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Article: What is the return on assets (ROA) ratio?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.